Trial
NCT02383433
Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Case Comprehensive Cancer Center
Collaborators
National Cancer Institute (NCI)
Condition
Metastatic Pancreatic Adenocarcinoma
Intervention
Regorafenib
Why stopped
PI discretion based on low accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-10-23